Your session is about to expire
← Back to Search
GMFFP Transfusions for Frailty
Study Summary
This trial is testing the safety and efficacy of 12 monthly transfusions of GMFFP to improve cognitive function, quality of life, and frailty index in older adults.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Could I potentially qualify to participate in this medical research?
"Eligible patients for this trial must have frailty and be between 55 and 95 years of age. The study is hoping to enroll around 30 individuals total."
Are there other examples of GMFFP being tested in a controlled setting?
"Out of the 168 ongoing trials studying GMFFP, 37 are in Phase 3. Although most of these investigations into GMFFP are based out of Saint Louis, Missouri, there are actually 4,670 trial locations for this potential treatment."
Are recruitment efforts for this research still ongoing?
"This research is not currently looking for test subjects. The trial was first announced on February 5th, 2018 and the most recent update was on May 5th, 2022. There are other options available; as of right now, there are 154 clinical trials actively admitting patients with frailty and 168 trials for GMFFP that need participants."
What are some conditions that GMFFP has been shown to improve?
"Febrile neutropenia, neutropenia, and infection can all be treated by using GMFFP."
Does this research project welcome young adults as participants?
"Patients who meet the age requirement of 55 to 95 years old are eligible for this clinical trial. In contrast, there are 85 trials aimed at people below 18 and 255 for senior citizens."
Share this study with friends
Copy Link
Messenger